Temozolomide

Clinical study of temozolomide for refractory malignant glioma

替莫唑胺治疗难治性恶性脑胶质瘤临床观察

Clinical observation of temozolomide combined with radiotherapy for 18 cases of newly diagnosed high grade gliomas

替莫唑胺联合放疗治疗18例初诊高级别脑胶质瘤患者的临床观察

Studies on determination of temozolomide in plasma by HPLC and its pharmacokinetics in mice

小鼠血浆中替莫唑胺HPLC测定及药动学研究

The Study of Anti-human Glioma Cells by Temozolomide Combined with Targeted Drugs in Vitro

替莫唑胺及其联合分子靶向药物抗人脑胶质瘤细胞体外试验性研究

Temozolomide United rituximab in the treatment of recurrent Central nervous system lymphoma ( a case report )

替莫唑胺联合美罗华治疗复发中枢神经系统淋巴瘤（附1例报告）

Clinical Analysis of Efficacy Preventing Brain Metastases Treated with Temozolomide and Biotherapy in Malignant Melanoma

替莫唑胺联合生物疗法预防晚期黑色素瘤脑转移临床分析

Objective : To develop a method so as to determine the related substances in the temozolomide hexyl ester .

目的：建立替莫唑胺酯中有关物质的测定方法。

RP-HPLC Diode Array Detector for Determination of the Related Substances in the Temozolomide Hexyl Ester

反相离子对色谱二极管阵列检测器测定替莫唑胺酯原料的有关物质

Objective To compare the curative effects and safety of temozolomide plus radiotherapy in the treatment of post-operative malignant glioma .

目的通过对比观察脑恶性胶质瘤术后替莫唑胺胶囊联合外放射治疗的疗效及安全性。

Therapeutic effect of local implantation with temozolomide / PLGA microsphere in treatment of rat C6 glioma in vivo

替莫唑胺缓释微球局部植入治疗大鼠脑胶质瘤的疗效

Objective : To summarize experiences of nursing care of malignant brain neurogliocytoma patients undergoing perioral temozolomide as chemotherapy .

总结恶性脑胶质瘤病人口服化疗药物替莫唑胺的护理体会。

MGMT gene silencing and benefit from temozolomide in glioblastoma

MGMT基因沉默和替莫唑胺治疗胶质母细胞瘤

Temozolomide chemotherapy : 75mg / m ~ 2 / day , orally intake for 6 weeks .

替莫唑胺化疗：75mg/m~2/天，口服，共6周。

The Mechanism of Thalidomide and Temozolomide Inhibition on Adhesion , Invasion and Integrin α v β 3 Expression in Human Glioblastoma Cells

沙利度胺与替莫唑胺抑制胶质瘤细胞黏附、侵袭以及整合素表达机制的研究

At recurrence temozolomide is effective for anaplastic tumors ; well-tolerated and probably equally effective is PCV used as adjuvant therapy .

对于复发的病人，替莫唑胺对间变胶质瘤是有效的。作为辅助治疗，它和PCV方案有同等的效果。

Conclusions Temozolomide plus radiotherapy is more effective than intraradiotherapy or chemotherapy alone in the treatment of malignant glioma and is well tolerated .

结论术后替莫唑胺胶囊联合外放射治疗胶质瘤的效果要好于单纯内放疗或化疗，病人对联合治疗有较好的耐受性。

Objective : To observe the curative efficacy of three-dimensional conformal radiotherapy ( 3D-CRT ) combined with temozolomide ( TMZ ) treatment for malignant glioma after surgery by retrospective analysis .

目的：通过回顾性分析研究恶性脑胶质瘤手术后采用现代三维立体适形放疗（3D-CRT）联合替莫唑胺（TMZ）化疗综合治疗的疗效。

Use of modern three-dimensional conformal radiotherapy ( 3D-CRT ) combined with temozolomide ( TMZ ) chemotherapy for treatment of patients with an average survival time and median survival time was 17.1377 and 19.3000 .

采用现代三维立体适形放疗（3D-CRT）联合替莫唑胺（TMZ）化疗综合治疗的患者平均生存时间和中位生存时间分别为17.1377个月和19.3000个月。

In addition , miR-21 dysregulation has been reported to be a predictor of tumor responses to conventional cytotoxic chemotherapeutic agents , such as gemcitabine , docetaxel , temozolomide and 5-fluorouracil .

此外，异常表达的miR-21可以预测肿瘤对传统化疗药物，如吉西他滨，多西他赛，替莫唑胺，5-氟尿嘧啶等的反应。

In experiment group temozolomide capsule ( 150 mg / m2 BSA ) was given orally in 1 st-5 th day and simulated lomustine capsule ( placebo ) 130 mg / m2 BSA was given while in the 1 st day .

试验组：按150mg/m2体表面积计算，25例患者于试验第1～5天口服替莫唑胺胶囊。第1天需同时口服环己亚硝脲安慰剂，剂量为130mg/m2。